Voretigene Neparvovec

Midwest CEPAC

ICER will develop a report assessing the comparative clinical effectiveness and value of voretigene neparvovec (LuxturnaTM, Spark Therapeutics), a potentially one-time gene therapy for vision loss associated with biallelic RPE65-mediated retinal disease. Voretigene neparvovec is the first gene therapy to be approved by the US Food and Drug Administration (FDA).

Date of review: January 2018


For questions or additional information, please contact info@icer-review.org

Associated Meetings

January 25, 2018 10am-4pm CT

Courtyard Marriott at Briarcliff
4000 North Mulberry Drive
Kansas City, MO

The Midwest CEPAC convened to deliberate on ICER's report on voretigene neparvovec (LuxturnaTM, Spark Therapeutics).

Key Dates

Associated Materials